skip to search skip to navigation skip to main content

Research & Development

Astellas Pharma Global Development Europe (APGD-EU) stands at the leading edge of science and technology.

Our Research and Development (R&D) strategy focuses on the acceleration and commercialisation of new drugs by concentrating resources on promising projects within clearly defined therapeutic areas.

Astellas Pharma Global Development Europe assumes global responsibility for R&D development in:

  • Urology
  • Diabetes/Metabolism/Kidney/Cardiovascular Disease
  • Pain Management

Astellas Pharma Global Development Europe also supports global R&D development efforts in the therapeutic areas (TAs) of:

  • Transplantation
  • Inflammation/Immunology (including Gastrointestinal Diseases)
  • CNS
  • Infectious Diseases
  • Oncology

Worldwide, Astellas has a significant number of major projects in Phase 3 or pending approval, and many more in early-phase clinical development.

We aim to be category leaders within focused therapeutic areas in order to improve the quality of life for patients, their families, and the caregivers who serve them.

Drug discovery and development process at Astellas:

Discovery Exploratory Development Full Development Post-Approval
Find the candidate to best test the hypothesis Test the candidate for its nonclinical and clinical safety, toleration, PK/PD, and pharmacological attributes vs the discovery hypothesis Develop the candidate into a drug by confirming its clinical attributes and safety in the treatment of specific diseases, conditions or indications Continue to develop the candidate post-approval; develop a risk management plan; fulfil all legal obligations of the Marketing Authorisation Holder for registered products

 

Privacy Policy  |  Terms of Use Copyright © 2017 Astellas Pharma